Madopar HBS and the decompensated phase of Parkinson disease.
The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling "off" periods, we added Madopar HBS to the previous treatment in such a way as to control these "off" phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.
Caraceni
T
T
Centro per le Malattie Extrapiramidali, Istituto Nazionale Neurologico C. Besta, Milano.
Nordera
N
N
Lamperti
E
E
Lorizio
A
A
D000328:Adult; D000368:Aged; D001545:Benserazide / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000503:physiopathology
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide